Discover how Plus Therapeutics Inc. is scaling REYOBIQ manufacturing for pivotal trials and what it means for radiopharmaceutical innovation.
Cellectar Biosciences, Inc. begins CLR 125 Phase 1b in refractory TNBC. Read what this could mean for precision radioconjugate oncology.
Plus Therapeutics has named Eric J. Daniels as Chief Development Officer. Read what this means for REYOBIQ, CNS oncology execution, and pipeline risk.
Radiopharm Theranostics reports strong RAD 101 interim data in brain metastases imaging. Read expert analysis on clinical impact and regulatory outlook.
TAG1 and Dana-Farber partner to expand Lead-212 access for targeted alpha therapies. Discover what this means for radiopharmaceutical oncology innovation.
BIOEMTECH secures Actinium-225 supply from NorthStar. Find out why isotope access now defines radiopharmaceutical development timelines.
Can Aktis Oncology’s IPO jumpstart alpha radiopharma? Find out what its $318M raise means for solid tumor treatment and VC-to-IPO biotech strategy.
Curasight A/S has dosed the first patient in a Phase 1 clinical trial of uTREAT for glioblastoma, launching the therapeutic half of its uPAR-targeting theranostic platform alongside its companion diagnostic, uTRACE, which is already in Phase 2 for prostate cancer. How curative ambitions shift when a theranostic platform enters human testing in glioblastoma Curasight’s advancement […]